Skip to content

Study · Animal study (in vivo) · mouse · 2026

3 results

TREM1-mediated macrophage activation drives voriconazole-induced hepatic steatosis: Diagnostic and therapeutic implications.

Liu J, Deng M, He X, Ma J, Zhang L, Yang X, Dai J, Dong S, Zhang Y, Zhang Z, Ying S, Hu H and 4 more

Show all authors

Jiang L, Wang Y, Qiu Y, Lou Y

Journal of pharmaceutical analysis6 Jan 2026

PMID42403941 (opens in a new tab)PMCIDPMC13331805 (opens in a new tab)DOI10.1016/j.jpha.2025.101540 (opens in a new tab)PepBankPUB-42403941
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In murine models of voriconazole-associated steatosis, LR12 suppressed TREM1 signaling.

    In plain wordsIn mice, LR12 suppressed TREM1 signaling in models of voriconazole-associated liver fat accumulation.

    Peptide
    Nangibotide
    Outcome
    DecreaseTREM1 signaling
    Study

    mousen: not reported in source

    Voriconazole-associated hepatic steatosis
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pharmacological inhibition of TREM1 (LR12 peptide) suppressed TREM1 signaling and attenuated both inflammatory and metabolic alterations in murine models.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In murine models of voriconazole-associated steatosis, LR12 attenuated inflammatory alterations.

    In plain wordsIn mice, LR12 reduced inflammatory changes in models of voriconazole-associated liver fat accumulation.

    Peptide
    Nangibotide
    Outcome
    DecreaseInflammatory alterations
    Study

    mousen: not reported in source

    Voriconazole-associated hepatic steatosis
    Outcome group
    Inflammation markers · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pharmacological inhibition of TREM1 (LR12 peptide) suppressed TREM1 signaling and attenuated both inflammatory and metabolic alterations in murine models.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In murine models of voriconazole-associated steatosis, LR12 attenuated metabolic alterations.

    In plain wordsIn mice, LR12 reduced metabolic changes in models of voriconazole-associated liver fat accumulation.

    Peptide
    Nangibotide
    Outcome
    DecreaseMetabolic alterations
    Study

    mousen: not reported in source

    Voriconazole-associated hepatic steatosis
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pharmacological inhibition of TREM1 (LR12 peptide) suppressed TREM1 signaling and attenuated both inflammatory and metabolic alterations in murine models.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.